Edition:
India

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

3,899JPY
4 Dec 2020
Change (% chg)

¥59 (+1.54%)
Prev Close
¥3,840
Open
¥3,855
Day's High
¥3,930
Day's Low
¥3,847
Volume
6,098,100
Avg. Vol
4,507,937
52-wk High
¥4,526
52-wk Low
¥2,894

Latest Key Developments (Source: Significant Developments)

Moderna Says Partners With Takeda, Govt Of Japan To Supply 50 Mln Doses Of Co's COVID-19 Vaccine Candidate
Thursday, 29 Oct 2020 

Oct 29 (Reuters) - Moderna Inc ::MODERNA PARTNERS WITH TAKEDA AND THE GOVERNMENT OF JAPAN TO SUPPLY 50 MILLION DOSES OF MRNA VACCINE AGAINST COVID-19 (MRNA-1273) TO JAPAN.MHLW AND TAKEDA WILL IMPORT AND DISTRIBUTE MRNA-1273 IN JAPAN STARTING IN FIRST HALF OF 2021.MODERNA-CO RESPONSIBLE FOR ALL IMPORT,LOCAL REGULATORY,DEVELOPMENT,DISTRIBUTION ACTIVITIES IN JAPAN TO ENSURE TIMELY ACCESS STARTING FIRST HALF OF 2021.  Full Article

Kamada Sees FY 2020 Revenue $132 Million To $137 Million
Wednesday, 7 Oct 2020 

Oct 7 (Reuters) - Kamada Ltd ::SEES FY 2020 REVENUE $132 MILLION TO $137 MILLION.EXPECTS TO RECEIVE $25 MILLION IN REVENUES FROM SALES OF GLASSIA TO TAKEDA IN 2021.PROJECTS ROYALTIES FROM TAKEDA IN RANGE OF $10 MILLION TO $20 MILLION PER YEAR FROM 2022 TO 2040.TAKEDA ANTICIPATES THAT ITS 2021 GLASSIA DEMAND FROM KAMADA WILL NOT EXCEED MINIMUM COMMITMENT UNDER SUPPLY AGREEMENT.FY2020 REVENUE VIEW $134.9 MILLION -- REFINITIV IBES DATA.  Full Article

Xenetic Biosciences - Announces Publication Of Data From Partner Takeda's Phase 1/2 Study
Tuesday, 14 Jan 2020 

Jan 14 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::XENETIC BIOSCIENCES - ANNOUNCES PUBLICATION OF DATA FROM PARTNER TAKEDA'S PHASE 1/2 STUDY EVALUATING PROGRAM LEVERAGING POLYXEN(R) PLATFORM TECHNOLOGY.  Full Article

Evotec, Takeda Enter Collaboration Across Multiple Therapeutic Fields
Tuesday, 24 Sep 2019 

Sept 24 (Reuters) - Evotec Se ::DGAP-NEWS: EVOTEC AND TAKEDA ENTER COLLABORATION AGREEMENT TO DISCOVER CLINICAL CANDIDATES ACROSS MULTIPLE THERAPEUTIC AREAS.MULTI-YEAR SMALL MOLECULE DRUG DISCOVERY COLLABORATION WITH A RISK SHARING, SUCCESS DRIVEN MODEL.EVOTEC LEADS INTEGRATED PROGRAMMES WITH TAKEDA HAVING OPTIONS AT LEAD SERIES AND CANDIDATE.EVOTEC RECEIVES UNDISCLOSED UPFRONT PAYMENT AND CAN EARN FUTURE MILESTONE AND ROYALTY PAYMENTS.PARTIES AIM TO ESTABLISH AT LEAST FIVE DRUG DISCOVERY PROGRAMMES WITH GOAL OF EVOTEC DELIVERING CLINICAL CANDIDATES FOR TAKEDA TO PURSUE INTO CLINICAL DEVELOPMENT.EVOTEC IS ELIGIBLE TO RECEIVE PRE-CLINICAL, CLINICAL, AND COMMERCIAL MILESTONES THAT CAN TOTAL IN EXCESS OF $ 170 M PER PROGRAMME AS WELL AS TIERED ROYALTIES ON FUTURE SALES.  Full Article

Kamada Reports Discussions With Takeda Regarding A Potential Extension Of The Period For The Transition Of Glassia Manufacturing To Takeda
Thursday, 8 Aug 2019 

Aug 8 (Reuters) - Kamada Ltd ::KAMADA REPORTS DISCUSSIONS WITH TAKEDA REGARDING A POTENTIAL EXTENSION OF THE PERIOD FOR THE TRANSITION OF GLASSIA MANUFACTURING TO TAKEDA.KAMADA LTD - GLASSIA SUPPLY AGREEMENT WITH TAKEDA CURRENTLY EXTENDS THROUGH END OF 2020.KAMADA LTD - TRANSITION OF GLASSIA MANUFACTURING TO TAKEDA AFTER 2020 WILL RESULT IN A SIGNIFICANT REDUCTION OF KAMADA'S REVENUES.KAMADA LTD - BASED ON CURRENT TERMS OF SUPPLY AGREEMENT, KAMADA WOULD BE ENTITLED TO FUTURE ROYALTY PAYMENTS UNTIL 2040..  Full Article

Takeda Says Investigational Subcutaneous Formulation Of Vedolizumab Meets Primary Endpoint In Achieving Clinical Remission At Week 52 In Patients With Moderately To Severely Active Crohn's Disea
Monday, 22 Jul 2019 

July 22 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::INVESTIGATIONAL SUBCUTANEOUS FORMULATION OF VEDOLIZUMAB MEETS PRIMARY ENDPOINT IN ACHIEVING CLINICAL REMISSION AT WEEK 52 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE.VEDOLIZUMAB SUBCUTANEOUS CURRENTLY UNDER REVIEW FOR APPROVAL FOR ULCERATIVE COLITIS WITH EUROPEAN MEDICINES AGENCY, U.S. FDA.  Full Article

Molecular Templates Announces FDA Acceptance Of IND Application For TAK-169, An Engineered Toxin Body Targeting CD38
Monday, 17 Jun 2019 

June 17 (Reuters) - Molecular Templates Inc ::MOLECULAR TEMPLATES ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR TAK-169, AN ENGINEERED TOXIN BODY TARGETING CD38.MOLECULAR TEMPLATES INC - CO, TAKEDA CO-DEVELOPING TAK-169.  Full Article

Skyhawk Therapeutics Announces Agreement With Takeda To Develop Novel Small Molecule Rna Splicing Modifiers
Monday, 6 May 2019 

May 6 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::SKYHAWK THERAPEUTICS ANNOUNCES AGREEMENT WITH TAKEDA TO DEVELOP NOVEL SMALL MOLECULE RNA SPLICING MODIFIERS FOR NEURODEGENERATIVE DISEASES.  Full Article

Exelixis' Partner Takeda Announces Filing Of NDA In Japan For Cabometyx For Advanced Renal Cell Carcinoma
Thursday, 25 Apr 2019 

April 25 (Reuters) - Exelixis Inc ::EXELIXIS’ PARTNER TAKEDA ANNOUNCES FILING OF NEW DRUG APPLICATION IN JAPAN FOR CABOMETYX® (CABOZANTINIB) FOR ADVANCED RENAL CELL CARCINOMA.EXELIXIS INC - REGULATORY SUBMISSION TRIGGERS $10 MILLION MILESTONE PAYMENT TO EXELIXIS UNDER COLLABORATION AND LICENSE AGREEMENT WITH TAKEDA.EXELIXIS INC - EXELIXIS WILL RECEIVE A $10 MILLION MILESTONE PAYMENT FROM TAKEDA, ANTICIPATED TO BE RECEIVED IN Q2 OF 2019.EXELIXIS INC - SUBMISSION BASED ON METEOR AND CABOSUN TRIALS AS WELL AS TAKEDA BRIDGING STUDY.  Full Article

LegoChem Biosciences, Takeda Enter into Multi-Target Research Collaboration and License Agreement
Friday, 22 Mar 2019 

March 22 (Reuters) - LegoChem Biosciences Inc <141080.KQ>::LEGOCHEM BIOSCIENCES, TAKEDA ENTER INTO MULTI-TARGET RESEARCH AND LICENSE AGREEMENT FOR DEVELOPMENT OF ANTIBODY-DRUG CONJUGATES IN IMMUNO-ONCOLOGY.TAKEDA OBTAINS RIGHTS TO LCB'S ADC PLATFORM FOR MULTIPLE TARGETS.LCB WILL RECEIVE $7.25 MILLION IN UPFRONT AND NEAR-TERM MILESTONE PAYMENTS..LCB ELIGIBLE TO RECEIVE DEVELOPMENT, REGULATORY, COMMERCIAL MILESTONE PAYMENTS OF UP TO $404 MILLION.LCB ELIGIBLE TO RECEIVE ROYALTIES ON SALES OF ANY RESULTING ADC PRODUCTS.  Full Article

Photo

Japan's Takeda eyes new focus on vaccines after OTC asset sales - CEO

TOKYO Japan's Takeda Pharmaceutical Co is looking at making vaccines a core business after completing asset sales to lower debt following its takeover of Shire Plc, Chief Executive Christophe Weber said.